Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients.

Abstract

BACKGROUND:

This study aimed to report the clinical and outcome data from a large cohort of patients diagnosed with acromegaly and treated at our institution over a 20-year period.

METHODS:

Sixty-two acromegaly patients (32 women and 30 men) treated and monitored at the endocrinology polyclinic between 1984 and 2013 were enrolled in this retrospective study. Clinical features and patients' treatment outcomes were evaluated. A level of growth hormone (GH) of <2.5 ng/ml was considered as the criterion for remission, and the normal insulin-like growth factor (IGF) range was based on gender and age.

RESULTS:

The mean age at the time of diagnosis was 38.8 ± 1.4 years, the time to diagnosis was 4.5 ± 0.3 years, and the follow-up duration was 7.3 ± 0.8 years. Among patients' symptoms, growth in hands and feet and typical facial dysmorphism were the most prominent (92%). The number of patients with diabetes mellitus, hypertension and hyperprolactinemia were 22 (35%), 13 (21%) and 13 (21%), respectively. Microadenomas and macroadenomas were found in eight and 54 patients, respectively. A significant correlation was found between the initial tumor diameters and GH levels (p = 0.002). The mean GH and IGF-1 levels were 39.18 ± 6.1 ng/ml and 993.5 ± 79 ng/ml, respectively. Visual field defect was found in 16 patients (32%). Thirty-one patients were treated by transsphenoidal surgery. Four of these were cured, 10 patients developed postoperative anterior pituitary hormone deficiency, and one patient developed diabetes insipidus. Twenty patients were treated by transcranial surgery, of which two were cured, while 17 patients developed postoperative anterior pituitary hormone deficiency. In total, five of the patients who were not cured after surgery were given conventional radiotherapy, of which two were cured. Four of 15 patients, on whom Gamma Knife radiosurgery was performed, were cured. Biochemical remission was achieved in 32 of 52 patients who received octreotide treatment, and in two of five patients who received lanreotide treatment.

CONCLUSIONS:

The rate of surgical success in our patients was found to be low. This could be explained by an absence of experienced pituitary surgical centers or surgeons in our region, and the fact that most patients presented late at the macroadenoma stage.

• Authors: Mehtap Evran, Murat Sert, Tamer Tetiker
• Journal: BMC endocrine disorders (BMC Endocr Disord) Vol. 14 Pg. 97 (Dec 16 2014) ISSN: 1472-6823 [Print] England
• PMID: 25511633 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Peptides, Cyclic
• lanreotide
• Human Growth Hormone
• Somatostatin
• Insulin-Like Growth Factor I
• Octreotide

Topics

• Acromegaly (blood, drug therapy, surgery, therapy)
• Adult
• Antineoplastic Agents, Hormonal (therapeutic use)
• Female
• Follow-Up Studies
• Human Growth Hormone (blood)
• Humans
• Insulin-Like Growth Factor I (metabolism)
• Male
• Octreotide (therapeutic use)
• Peptides, Cyclic (therapeutic use)
• Radiosurgery
• Retrospective Studies
• Somatostatin (analogs & derivatives, therapeutic use)
• Time Factors
• Treatment Outcome